Blog
RSS FeedPosted by Michael Wonder on 30 Nov 2023
Cabozantinib maleate with nivolumab for patients with untreated advanced renal cell carcinoma
30 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Nov 2023
Belzutifan for the treatment of patients with a tumour associated with von Hippel-Lindau disease
29 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Nov 2023
Rare Disorders NZ wants new Minister for PHARMAC to act swiftly to remove PHARMAC Chair
28 November 2023 - Rare Disorders NZ has today written to the new Minister for PHARMAC, David Seymour, reiterating their ...
Posted by Michael Wonder on 29 Nov 2023
Tisagenlecleucel for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
29 November 2023 - NICE is unable to make a recommendation on the use of tisagenlecleucel (Kymriah) for the treatment of ...
Posted by Michael Wonder on 29 Nov 2023
Foslevodopa with foscarbidopa for the treatment of patients with advanced Parkinson’s with motor symptoms
29 November 2023 - NICE has published final evidence-based recommendations on the use of foslevodopa with foscarbidopa (Produodopa) for the ...
Posted by Michael Wonder on 27 Nov 2023
Lifeline for Wolman disease kids as NICE backs Alexion drug
27 November 2023 - Infants with a rare and fatal congenital disorder called Wolman disease in England and Wales will ...
Posted by Michael Wonder on 24 Nov 2023
Ritlecitinib tosylate for the treatment of people with alopecia areata
24 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 23 Nov 2023
Cedazuridine with decitabine for patients with untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
23 November 2023 - NICE is unable to make a recommendation on the use of cedazuridine with decitabine (Inaqovi) for the ...
Posted by Michael Wonder on 22 Nov 2023
Agenda for the March 2024 PBAC meeting
22 November 2023 - The agenda for the March 2024 PBAC meeting is now available. ...
Posted by Michael Wonder on 22 Nov 2023
Zanubrutinib for the treatment of patients with chronic lymphocytic leukaemia (final guidance)
22 November 2023 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of ...
Posted by Michael Wonder on 22 Nov 2023
Updates to the HTA Review Research and Analysis papers collection: draft HTA expert paper published
22 November 2023 - The draft paper 'Optimising the availability and use of real world data and real world evidence to ...
Posted by Michael Wonder on 20 Nov 2023
NICE gets ready to assess new dementia treatments
20 November 2023 - NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the ...
Posted by Michael Wonder on 16 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee (16 November 2023)
16 November 2023 - Two more documents are now available. ...
Posted by Michael Wonder on 15 Nov 2023
Early benefit assessment: meaningful RCTs are also feasible in late oncological treatment lines
15 November 2023 - Two randomised controlled studies in the third and fourth lines for colorectal and breast cancer each show ...
Posted by Michael Wonder on 15 Nov 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with metastatic PSMA positive hormone-relapsed prostate cancer after two or more treatments
15 November 2023 - NICE has published final evidence-based recommendations on the use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) ...